Behbahani Ali 4

What Happened

• Behbahani Ali, a non-employee director of Black Diamond Therapeutics (BDTX), was issued 6,919 shares of common stock on March 20, 2026. The shares are reported at $2.15 each (based on the March 19, 2026 close), for a total value of about $14,876. This transaction is an award/acquisition under the company’s director compensation policy (the reporting code is "A").

Key Details

• Transaction date: 2026-03-20; Price used: $2.15 (closing price on 2026-03-19).
• Shares acquired: 6,919; Reported total value: ~$14,876.
• Shares owned after transaction: Not disclosed in the filing.
• Footnotes: F1 — shares issued in lieu of cash under the Issuer’s Fifth Amended and Restated Non‑Employee Director Compensation Policy; F2 — price based on March 19, 2026 close; F3 — the reporting person is manager of certain NEA entities and disclaims beneficial ownership to the extent described in the filing.
• Timeliness: Filed on 2026-03-20 (period of report 2026-03-20); no late-filing flag indicated.

Context

• These shares were issued as director compensation elected in lieu of cash, a routine corporate practice that reflects pay rather than an open-market directional bet. Such awards are common for non-employee directors and don’t necessarily indicate the insider’s view of the stock.